F-star Biotech (Austria) a development-stage based biopharma company focused upon an antibody design platform, with product and indication(s) to be identified, closed a $10.8M Series A financing, bringing the total round to $25.8M. Participants include MP Healthcare Venture Management, Merck Serono Ventures, Atlas Venture, Aescap Venture, Novo Ventures and TVM Capital.

arGEN-X (Netherlands) a development-stage biopharmaceutical company focused on a monoclonal antibody platform with potential indications in autoimmunity, oncology and bone disease, closed a $4.5M Series A financing, bring total round proceeds to $18.3M. Participants have included Credit Agricole Private Equity, Forbion Capital Partners, Life Science Partners, KBC Private Equity, BioGeneration Ventures, Erasmus MC Biomedical Fund, [...]

Epizyme (Cambridge, MA) a development-stage biopharma company focused on histone methyltransferases inhibitors in oncology indications, closed a $8M Series B financings, bringing the total round to $40M. Participants include New Enterprise Associates, Bay City Capital, Amgen Ventures, Astellas Venture Partners, MPM Capital and Kleiner Perkins Caufield and Byers.
Note: 2009 Year-in-Review Trend Analysis Coming 15 [...]

Molecular Partners (Switzerland) a preclinical-stage developing DARPins, a potential new class of protein therapeutics focused on ophthalmology indications, closed a $45M Series B financing. Participants include Essex Woodlands Health Ventures, Index Ventures, Johnson & Johnson Development Corp., BB Biotech Ventures and EndeavourVision.

Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

Zyngenia (Rockville, MD) a pre-clinical stage biotherapeutics company focused on multi-specific antibodies for oncology and autoimmune disorders, closed a $10M Series A financing. Particpants include New Enterprise Associates.
Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

Epizyme (Cambridge, MA) a development-stage biopharma company focused on histone methyltransferases inhibitors in oncology indications. Participants include Bay City Capital, Amgen Ventures, Astellas Venture Management, MPM Capital and Kleiner Perkins Caufield and Byers.
Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb.

Crescendo Biologics (United Kingdom) a development-stage biopharma focused on a fragment antibody technology platforms, closed a $7.3M Series A financing. Participants include Sofinnova Partners, Aitua, Avlar BioVentures and Rainbow Seed Fund.

Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb.

Endocyte (West Lafayette, IN) a clinical-stage biopharmaceutical focused on folate-receptor targeted receptors in ovarian, NSCLC and breast cancers and renal cell carcinoma, closed a $26M Series B financing. Participants include Sanderling Ventures, Burrill & Co., American Bailey Ventures, Blue Chip Venture Co. and Triathlon Medical Ventures.
Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb.

Synageva BioPharma (Waltham, MA) a clinical-stage biopharma and developer of the Synageva Expression Platform, an integrated platform of vectors and protein production, processing and purification systems used to develop their pipeline of monoclonal antibodies, cytokines, and biosimilars, closed a $12M Series X financing bringing the total round to $45M. Participants include New Leaf Venture Partners, [...]

arGEN-X (The Netherlands) a development-stage biopharmaceutical company focused on a monoclonal antibody platform and potential applications in oncology and infectious disease, closed a $13.8M Series A financing. Participants include Forbion Capital Partners, Life Science Partners, KBC Private Equity, BioGeneration Ventures, Erasmus MC Biomedical Fund and Thuja Capital Healthcare.

NanoBio (Ann Arbor, MA) a clinical-stage company focused on topical antiinfectives and mucosal vaccines for the treatment and prevention of herpes labialis, onychomycosis, acne and cystic fibrosis closed a $10M Series B financing, bringing the total round to $22M. Participants include Perseus.

Avila Therapeutics (Waltham, MA) a preclinical-stage biopharmaceutical company focused on protein silencing drugs for viral infections, cancer and autoimmune diseases, closed a $30M Series B financing. Participants include Novartis Option Fund, Abingworth Management, Advent Venture Partners, Atlas Venture and Polaris Venture Partners.

Alios BioPharma (San Francisco, CA) a preclinical-stage small molecule and protein therapeutics company focused on viral disease via innate immune modulation, closed a $8M Series A financing bring the total round to $32M. Participants include SR One, Novo Ventures, Novartis Venture Fund and Roche Venture Fund.